• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Oman Pharmaceuticals and Healthcare Report Q1 2013 - Product Image

Oman Pharmaceuticals and Healthcare Report Q1 2013

  • Published: February 2013
  • Region: Oman
  • 85 pages
  • Business Monitor International

BMI View

Oman’s commendable public healthcare system and high-class tertiary and quaternary care hospitals will increase the uptake of medical tourism by GCC citizens. The Omani pharmaceutical market will continue to remain heavily reliant on imports due to the costly need to source raw ingredients for local manufacturing and lack of R&D backing. However, despite the strict drug pricing system, we are likely to see more multinational companies penetrating the market and expanding volume sales, by addressing the increasing burden of non-communicable diseases in the country.

Headline Expenditure Projections

- Pharmaceuticals: OMR151mn (US$391mn) in 2011 to OMR166mn in 2012; +9.9% in local currency terms and +11.3% in US dollar terms. Forecast revised upwards due to modifications to historical figures.

- Healthcare: OMR742mn (US$1.93bn) in 2011 to OMR839mn (US$2.21bn) in 2012; +13.1% in local currency terms and +14.6% in US dollar terms. Forecast revised upwards due to modifications to historical figures.

- Medical devices: OMR40mn (US$105mn) in 2011 to OMR44mn (US$116mn) in 2012; +9.5%
in local currency terms and +10.9% in US dollar terms. Forecast revised upwards due to modifications to historical figures.

Executive Summary 5

SWOT Analysis 7

Oman Pharmaceuticals And Healthcare Industry SWOT 7

Oman Political SWOT 8

Oman Economic SWOT 8

Oman Business Environment SWOT 9

Pharmaceutical Risk/Reward Ratings 10
Table: Middle East And Africa (MEA) Pharmaceutical Risk/Reward Ratings, Q113 10

Rewards 12

Risks 13

Oman - Market Summary 15

Regulatory Regime 17

Regulatory Developments 18

Intellectual Property Regime 18
Table: IP Laws In Oman 19

Regional Harmonisation 19

Pricing And Reimbursement Regime 20

Recent Pricing And Reimbursement Developments 21

Free Trade Agreements 22

Industry Developments 24

Epidemiology 24

Communicable Diseases 25

Non-Communicable Diseases 26

Public Health Developments 27

Healthcare Sector 28
Table: Number Of Health Centres In Oman By Region 28
Table: Number And Type Of Health Institutions In Oman 29

Healthcare System Developments 29
Table: Healthcare Reform Targets 31

Private Healthcare Sector 31

Private Healthcare Developments 32

Healthcare Funding 33

Healthcare Insurance 33

Telemedicine 34

Medical Tourism 34

Research And Biotechnology 36

Clinical Trials 37

Medical Devices 38

Industry Forecast Scenario 39

Overall Market Forecast 39
Table: Oman Pharmaceutical Sales, Historical Data And Forecasts, 2007-2017 40

Key Growth Factors - Industry 41
Table: Oman Healthcare Expenditure Trends, Historical Data and Forecasts 42
Table: Oman Government Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017 42
Table: Oman Private Healthcare Expenditure Trends, Historical Data And Forecasts, 2009-2017 43

Key Growth Factors - Macroeconomic 44
Table: Oman - GDP By Expenditure, Current Prices Breakdown, 2008-2016 48

Prescription Drug Market Forecast 49
Table: Oman Prescription Drug Market Indicators, Historical Data And Forecasts, 2009-2017 50

Patented Drug Market Forecast 51
Table: Oman Patented Drug Market Indicators, Historical Data and Forecasts 52

Generic Drug Market Forecast 53
Table: Oman Generics Drug Market Indicators, Historical Data And Forecasts, 2009-2017 54

OTC Medicine Market Forecast 55
Table: Oman Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts, 2009-2017 56

Pharmaceutical Trade Forecast 57
Table: Oman Pharmaceutical Trade Data And Forecasts (US$mn), 2009-2017 58
Table: Oman Pharmaceutical Trade Data And Forecasts (OMRmn), 2009-2017 58

Medical Device Market Forecast 59
Table: Oman Medical Device Market Indicators, Historical Data and Forecasts, 2009-2017 60

Other Healthcare Data Forecasts 61

Key Risks To BMI's Forecasts 62

Competitive Landscape 63

Pharmaceutical Sector 63

Domestic Industry 63

Foreign Industry 64

Pharmaceutical Distribution 65

Company Profiles 66

Local Companies 66

Zynova/Oman Pharmaceutical Products Company (OPPC) 66

National Pharmaceutical Industries (NPI) 68

Multinational Companies 70

Novartis 70

GlaxoSmithKline 72

Sanofi 73

Johnson & Johnson 74

Demographic Outlook 75
Table: Population By Age Group, 1990-2020 ('000) 76
Table: Population By Age Group, 1990-2020 (% of total) 76
Table: Key Population Ratios, 1990-2020 77
Table: Rural/Urban Population Split, 1990-2020 77

Glossary 79

BMI Methodology 81

How We Generate Our Pharmaceutical Industry Forecasts 81

Risk/Reward Ratings Methodology 82

Ratings Overview 82
Table: Pharmaceutical Business Environment Indicators 83

Weighting 84
Table: Weighting Of Components 84

Sources 84

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos